MoonLake Immunotherapeutics Asset Resilience Ratio
MoonLake Immunotherapeutics asset resilience ratio. MoonLake Immunotherapeutics (MLTX) has an Asset Resilience Ratio of 14.84% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See MLTX days of operational coverage to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of MoonLake Immunotherapeutics (2021–2025)
Asset resilience ratio of MoonLake Immunotherapeutics from 2021 to 2025. This chart shows how MoonLake Immunotherapeutics's Asset Resilience Ratio has changed over time. Read MoonLake Immunotherapeutics debt and liabilities for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down MoonLake Immunotherapeutics's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see MLTX total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $59.43 Million | 14.84% |
| Total Liquid Assets | $59.43 Million | 14.84% |
Asset Resilience Insights
- Moderate Liquidity: MoonLake Immunotherapeutics has 14.84% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
MoonLake Immunotherapeutics Industry Peers by Asset Resilience Ratio
Compare MoonLake Immunotherapeutics's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Verona Pharma plc
F:I9SA |
Biotechnology | 0.00% |
|
Centessa Pharmaceuticals PLC ADR
NASDAQ:CNTA |
Biotechnology | 33.37% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161 |
Biotechnology | 8.08% |
|
Bavarian Nordic
CO:BAVA |
Biotechnology | 10.83% |
|
Hebei Changshan Biochem Pharma
SHE:300255 |
Biotechnology | -0.03% |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287 |
Biotechnology | 37.31% |
MoonLake Immunotherapeutics Asset Resilience Ratio by Year (2021–2025)
MoonLake Immunotherapeutics asset resilience ratio by year from 2021 to 2025. The table below shows the annual Asset Resilience Ratio data for MoonLake Immunotherapeutics.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 14.01% | $59.45 Million | $424.43 Million | -41.98pp |
| 2024-12-31 | 55.99% | $267.60 Million | $477.93 Million | +44.63pp |
| 2023-12-31 | 11.36% | $59.84 Million | $526.54 Million | -31.07pp |
| 2022-12-31 | 42.44% | $32.61 Million | $76.84 Million | -- |
| 2021-12-31 | 0.00% | $0.00 | $9.68 Million | -- |
About MoonLake Immunotherapeutics
MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplan… Read more